Free Trial

Schrödinger (NASDAQ:SDGR) Posts Quarterly Earnings Results, Misses Estimates By $0.01 EPS

Schrödinger logo with Medical background

Schrödinger (NASDAQ:SDGR - Get Free Report) released its quarterly earnings data on Wednesday. The company reported ($0.82) earnings per share for the quarter, missing analysts' consensus estimates of ($0.81) by ($0.01), Zacks reports. The company had revenue of $59.55 million for the quarter, compared to analysts' expectations of $54.60 million. Schrödinger had a negative net margin of 91.84% and a negative return on equity of 35.77%. The business's revenue for the quarter was up 62.7% compared to the same quarter last year. During the same period last year, the company posted ($0.86) EPS. Schrödinger updated its FY 2025 guidance to EPS.

Schrödinger Stock Up 0.1%

Shares of NASDAQ:SDGR traded up $0.02 on Friday, hitting $23.90. The company had a trading volume of 1,127,872 shares, compared to its average volume of 842,665. The firm's 50-day simple moving average is $22.62 and its two-hundred day simple moving average is $21.82. Schrödinger has a 1 year low of $16.60 and a 1 year high of $28.47. The firm has a market capitalization of $1.75 billion, a price-to-earnings ratio of -10.21 and a beta of 1.84.

Wall Street Analysts Forecast Growth

SDGR has been the subject of a number of analyst reports. KeyCorp increased their price objective on Schrödinger from $30.00 to $32.00 and gave the company an "overweight" rating in a research note on Wednesday, April 16th. Piper Sandler reduced their price target on Schrödinger from $50.00 to $45.00 and set an "overweight" rating on the stock in a report on Thursday, February 27th. One analyst has rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and an average price target of $32.80.

View Our Latest Report on SDGR

Insider Transactions at Schrödinger

In other news, insider Karen Akinsanya sold 16,723 shares of the firm's stock in a transaction dated Monday, April 14th. The shares were sold at an average price of $25.09, for a total value of $419,580.07. Following the completion of the sale, the insider now directly owns 15,625 shares of the company's stock, valued at approximately $392,031.25. This trade represents a 51.70% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Geoffrey Craig Porges sold 5,491 shares of the firm's stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $21.76, for a total transaction of $119,484.16. Following the completion of the sale, the chief financial officer now directly owns 27,544 shares of the company's stock, valued at approximately $599,357.44. This represents a 16.62% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 8.60% of the company's stock.

About Schrödinger

(Get Free Report)

Schrödinger, Inc, together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries.

Read More

Earnings History for Schrödinger (NASDAQ:SDGR)

Should You Invest $1,000 in Schrödinger Right Now?

Before you consider Schrödinger, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Schrödinger wasn't on the list.

While Schrödinger currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

5 Blowout Earnings Winners That Could Soar Even Higher
5 Stocks You’ve Never Heard Of That I’m Buying Nonstop in 2025
3 Sectors With Massive Momentum You Can’t Afford to Miss

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines